News Articles 141 - 150 of 160
Protecting and improving the nation’s health.
New, more effective treatments are available for the hepatitis C virus (HCV), which can improve outcomes and cure the infection in most people.
To ensure as many eligible people as possible are treated, Public Health England is supporting the NHS in contacting people – and informing their GPs – if they have been diagnosed with HCV in the past but may not have cleared their infection. These patients will be offered a test to determine whether or not they have the active infection and, if so, will then be assessed for treatment.
Some people may be aware of their diagnosis and have cleared the infection spontaneously (1 in 5 people do) or have been successfully treated. However, if anyone is unsure of their HCV status and thinks they may be at risk, they should contact their GP to arrange testing.
Read the PHE and NHSE press release here > Download FINAL-4 HCV Monitoring Report Nov 18.pdf
For more information on HCV please visit: https://www.nhs.uk/conditions/hepatitis-c/
You can find the new PHE treatment report here: https://www.gov.uk/government/publications/hepatitis-c-treatment-monitoring-in-england
You can find assets for the reengagement exercise here: https://www.gov.uk/government/publications/hepatitis-c-patient-re-engagement-exercise
The final guidance for subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis is now available on the NICE website (November 2018) > https://www.nice.org.uk/guidance/published .
The IQILS accreditation scheme (Improving Quality in Liver Services) has now been operational for over a year. 2018 has been a busy year for the scheme, with 36 services registered to date.
A full list and map of those registered can be found on the website. Services across Wales, Northern Ireland and England are included in those registered. A few early bird discounts, available for smaller services, kindly supported by BASL, are still available. If your service would be interested in this, please get in touch at email@example.com .
The second service training day for registered services is being held in London on 29 January 2019. The day is designed for services that would like to learn more about the accreditation standards and the accreditation process. For further information, please contact the team.
Following an assessor training day held in September, the first batch of assessors have been recruited and trained. Wales is leading the way in improving liver services and with the help of an initiative funded by the Welsh government, with two peer review visits taking place in November 2018. The scheme is going from strength to strength and our hope is that we have more services registering with the scheme. Registration is open to all liver services across the UK.
Enter the 2018 BJN Awards today!
The British Journal of Nursing is delighted to welcome nominations into the BJN Awards 2019. A showcase of nursing excellence, the BJN Awards recognise and celebrate the individuals going above and beyond in delivering their care.
The nurse who goes above and beyond. The nurse who puts patient care at the heart of their role. The nurse who inspires you. The nurse who drives the profession. The nurse who deserves to be celebrated. We all know that nurse.
Please nominate for the Hepatology / Liver Nurse of the year category.
By nominating that nurse, you will not only be gaining them the recognition and reward they deserve, you will be doing your part to highlight the critical contribution nursing makes to healthcare.
Entries close on 19 November 2018 so nominate a colleague today by visitng the BJN website by clicking > here.
BASL has set up a number of Special Interest Groups (SIGs), which are linked to the NIHR’s Clinical Research Network (CRN) topic areas. The Wilson’s Disease SIG has been active for one year, with an initial lead appointed by the BASL Committee. BASL is now seeking nominations for an elected Lead for this SIG.
- All nominees should be members of the Wilson’s Disease SIG, as a BASL member or as an associate member of BASL through being a member of the SIG
- Each nominee should have a proposer and seconder, who should also be BASL members or associate members through the Wilson’s Disease SIG
- The initial Lead can stand for election once
- Should a contested election be held, BASL / Wilson’s Disease SIG members may vote in this
- The elected Lead will serve for two years, when there will be a further election.
- Please send nominations to the BASL Secretariat at Samantha@basl.org.uk by 17:00 on 19 November 2018
- If more than one candidate is nominated, the Secretariat will arrange for an election, in which all BASL / Wilson’s Disease SIG members may vote
- Should an election be required, candidates will need to submit a personal statement of up to 300 words
- The successful candidate will be elected by a simple majority of those members voting
- Any queries should be addressed to Samantha@basl.org.uk.
About the Wilson’s Disease SIG
The Wilson’s Disease SIG is linked to the Metabolic CRN topic area. The SIG comprises a variety of clinical and laboratory specialists from around the UK, Public Health England and patient representation from the Wilson’s Disease Support Group. Its aims are to foster closer collaboration for clinical and scientific research, provide a forum to discuss and disseminate best practice, and act as a stimulus towards Centres of Excellence for Wilson’s disease. Further information may be found here.
The role of the SIG Lead
A SIG is expected to meet at least once a year. The BASL secretariat provides administrative support for SIGs, which includes creating and maintaining SIG member databases, arranging meetings and associated materials, and arranging publicity.
The role of the SIG Lead includes:
- Chairing SIG meetings and co-ordinating actions to be pursued
- Helping to co-ordinate bids for funding for trials and other research, and linking with the NIHR and other funders
- Ensuring the SIG is recognised and supported within the Metabolic CRN topic area
- Reporting on SIG activities to BASL, in particular via liaison with BASL’s Research Subcommittee.
Gastrointestinal Nursing’s Liver Nursing Supplement is looking for a new member of its editorial board. Members of the board play a vital role in the success of the supplement by offering their expertise to review the quality and relevance of its content to readers. They advise the editor on article ideas, potential authors and the strategic direction of the journal.
Gastrointestinal Nursing is the foremost clinical journal for nurses working in hepatology, gastroenterology and stoma care, publishing research, reviews, case studies and opinion on patient care and professional development.
If you are interested in joining the editorial board, do have a look at the formal role description here; Download GIN Liver Nursing Supplement RD.pdf
To apply, send an email to Benjamin Wakefield. firstname.lastname@example.org with a little information about your present role and areas of expertise. You can also mention any relevant organisations you belong to, talks you have given or work you have published. Applicants will be chosen based on how well their expertise fits any gaps in the existing members’ knowledge base.
Closing date for applications is 1st December 2018.
Cancer Analyst for Analysis of the Epidemiology of Cholangiocarcinoma in England
Accountable to: AMMF/ PHE Senior Analyst
Duration: One year fixed term
Location: Flexible across national bases but post holder must be able to travel to London on a regular basis
Pay Grade: £27,527 - £33,098 (+ London Weighting if appropriate)
AMMF is the UK’s only dedicated cholangiocarcinoma charity, and works closely with Cholangiocarcinoma-UK (CCA-UK), a multidisciplinary UK-wide group interested in all facets of CCA and a Special Interest Group of BASL. AMMF is looking for a dedicated analyst with a strong statistical background and experience of routinely collected health data to work on an important epidemiological project on cholangiocarcinoma. This is an exciting opportunity to work on the most definitive study of cholangiocarcinoma epidemiology to date, in conjunction with AMMF, international experts in cholangiocarcinoma from Imperial College London and Public Health England’s (PHE) National Cancer Registration and Analysis Service (NCRAS).
Please email your CV together with a covering letter (max 500 words) to Helen Morement, CEO, AMMF at: email@example.com. For more information, please see:
or visit AMMF’s website: http://ammf.org.uk/vacancies/.
Closing date: 16 November 2018 at 5pm GMT
Interviews will be held w/c 3rd December 2018
The BASL Special Interest Groups (SIGs) are being established to foster, promote and encourage collaborative research and clinical trials in liver disease and are open to all members of BASL.
The SIGs are being aligned to the 7 topic areas recognised by the Hepatology CRN. BASL is keen to set up and establish a new SIG covering immune mediated liver disease and is asking for expressions of interest from BASL members to lead these SIGs for the first year, pending a formal election of post holders.
Please send expressions of interest to Samantha Jones at the BASL Secretariat Samantha@basl.org.uk by 31st October.
Public Health England (PHE) has developed the first ever clinically validated whole genome sequencing test for Hepatitis C virus (HCV) as part of a global effort to eliminate HCV by 2025. PHE will be the first place in the UK to offer a clinically validated test which looks at both viral strain and resistance in one test. The previous test PHE used involved two separate processes, one which identifies the strain and another which identifies the virus’ resistance. The new combined test took over 5 years to develop and will halves the current HCV diagnosis period from 20 to 10 days. This enables clinicians to provide patients with quicker access to curative treatment plans, thus reducing complications of the disease. Clinicians will also see a £130 saving per test compared to the existing system. PHE hopes that as the first WGS test for viruses this will serve as a model for other viruses such as HIV.
You can find out more about requesting a test here: https://www.gov.uk/guidance/antiviral-unit-avu-reference-services .
The link to the HCV testing request form can be found here: https://www.gov.uk/government/publications/hcv-genotypic-susceptibility-testing-request-form
Two new hepatology trials have been discussed and intellectually supported by the BSG-BASL Liver Research Development Group. These are supported from the NIHR HTA funding stream.
Beta Blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP) is a UK wide multi-centre liver study. It will address whether primary prophylaxis against future variceal haemorrhage with non-selective beta blockers is clinically and economically effective in patients with cirrhosis and small varices. £2.3 million will be provided to consent, treat and follow up 1,200 patients at 25 different hospitals across the UK. The trial is led by the Institute of Liver Sciences, King’s College Hospital and King’s College London Clinical Trials Unit. For more information: Download Press release BOPPP_FINAL_19.09.2018.pdf.
Antibiotic SpontanEous PeritoniTIs Cirrhosis (ASEPTIC) is a double blind placebo controlled trial to determine whether primary antibiotic prophylaxis with Cotrimoxazol substantially reduces the incidence of spontaneous bacterial peritonitis (SBP) in people with advanced liver disease. This will be the largest study of SBP prophylaxis ever, involving patients at 30 sites. The trial is led by Unveristy College London. For more information: Download ASEPTIC trial information for BSG and BASL.pdf.